Horizon Pharma announces end of phase 3 trial of the single-eye anti-eye drug teprotumumab treatment TED

today, Horizon Pharma announced that it had previously receivedThe FDA's(http://'s breakthrough therapy determined that orphan drug eligibility and fast-track eligibility in the study of single-eye anti-eye drug teprotumumab, in the treatment of active stage thyroid eye disease (TED) in the 3th phase of thetrial(http://, reached the primary and all secondary endpointsTeprotumumab's listing application is expected to be submitted to the FDA by the middle of this yearTeprotumumab is a fully human-derived monoclonal antibody of the insulin-like growth factor 1 receptor (IGF-1R)IGF-1R, which is closely related to the occurrence of TED, has a complex network of signaling pathways and abnormally high levels in the patient's eye fibroblastsstudies have shown that Teprotumumab blocks IGF-1R, resulting in lower levels of IGF-1 and TSH activity in the patient's eye cellsThe results of the 3rd phase of the OPTIC trial showed that the test reached the main endpoint of significantly improving eyeproscentAfter 24 weeks of administration, 82.9% of the teprotumumab group and 9.5% of patients in the placebo group achieved areduction in eye prominence of 2 mm or more (p 0.001)Detailed three trial data will be submitted to a peer-reviewed journal and will be published later this year at the medicalConference(http://